BIOLOGICAL PROPERTIES OF SV40 EARLY PROTEINS
SV40 早期蛋白的生物学特性
基本信息
- 批准号:3165852
- 负责人:
- 金额:$ 19.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1978
- 资助国家:美国
- 起止时间:1978-01-01 至 1994-06-30
- 项目状态:已结题
- 来源:
- 关键词:antibody formation antigen receptors athymic mouse cell line disease /disorder model gene expression genetic transcription hamsters immunochemistry laboratory mouse laboratory rabbit laboratory rat membrane activity molecular oncology mutant oncogenes oncogenic virus radiotracer simian virus 40 surface antigens tissue /cell culture transforming growth factors transforming virus tumor antigens viral leukemogenesis virus antigen virus genetics virus protein virus replication
项目摘要
The long-range goal of this project is to understand the transforming
interactions between DNA tumor virus and target cells. The approach has
been to define molecular interactions and biological functions expressed
by the SV40 transforming protein, large tumor antigen (T-ag). There is
evidence for multiple effects exerted by distinct T-ag subpopulations on
transformed cells, including possible role for plasma-membrane-associated
T-ag (pmT-ag). This renewal application focuses on questions fundamental
to understanding the molecular mechanisms of SV40 carcinogenesis. This
program will correlate T-ag structure and function with transformation
events.
The following specific aims are present. (1) The structure and function
of SV40 T-ag containing, membrane-associated protein complexes will be
analyzed. We have developed a butane extraction method that selectively
recovers membrane protein complexes that contain pmT-ag and p53-related
protein (p56). Other cellular components in the complexes (60K, 50K,
45K, 35K) will be identified; it is hypothesized they are members of a
receptor complex. the composition modifications, and biochemical
activities of pmT-ag-containing complexes will be investigated .
Possible involvement of T-ag in a growth-factor-like pathway will be
examined. (2) Transformation phenotypes of new in-phase deletion mutants
will be related to specific interactions of mutant T-89 with cellular
proteins and the plasma membrane. Different assays will distinguish T-ag
domain required for cell immortalization and phenotypic transformation.
Complementation transformation tests may permit assignment of T-ag
functions to categories defined by known oncogenes. Mutant T-ag
polypeptides will be characterized structurally and biochemically,
including complex formation with membrane proteins, and those analyses
correlated with transformation by the mutants. (3)Trafficking of SV40 T-
ag to the cell surface will be studied. Deletion mutants will reveal
possible effects of the short hydrophobic sequence in T-ag on transport
and membrane interaction. The potential involvement of cellular heat-
shock protein p73 (that bind T-ag) in pmT-ag transport will be addressed.
A role for O-glycosylation o T-ag in trafficking or membrane association
will be considered. (4) Cellular and molecular events involved in muoti-
stage carcinogenesis in livers of SV40 transgenic mice will be defined.
We have found that mice with the WT T-ag gene controlled by the alpha-1-
antitrypsin promoter develop liver tumors. New transgenic mice carrying
the p53 or mutants T-ag genes will be made. Various transgenic lines
will be crossed and pathology in progeny animal determined. The
expression of viral (pmT-ag and cellular (oncogenes) events will be
correlated with different stages of neoplastic progression. Hyperplastic
liver cells will be cultured to determine in vitro growth properties that
correspond to preneoplasia in vivo.
本项目的长期目标是了解
DNA肿瘤病毒和靶细胞之间的相互作用。 该方法具有
定义了分子间的相互作用和生物学功能
由SV 40转化蛋白、大肿瘤抗原(T-ag)引起。 有
不同的T-ag亚群对
转化细胞,包括质膜相关的可能作用,
T-ag(pmT-ag)。 此更新应用程序侧重于基本问题
了解SV 40致癌的分子机制。 这
程序将T-ag结构和功能与转化相关联
事件
提出了以下具体目标。(1)结构和功能
含SV 40 T-ag的膜相关蛋白复合物将
分析了 我们开发了一种丁烷提取方法,
回收含有pmT-ag和p53相关的膜蛋白复合物,
蛋白(p56)。 复合物中的其他细胞组分(60 K,50 K,
45 K,35 K)将被识别;假设他们是一个
受体复合物 化学成分的改变,
将研究含pmT-Ag复合物的活性。
T-ag可能参与生长因子样途径,
考察 (2)新的同相缺失突变体的转化表型
将与突变T-89与细胞的特异性相互作用有关。
蛋白质和质膜。不同的检测将区分T-ag
细胞永生化和表型转化所需的结构域。
互补转化试验可能允许T-ag的分配
根据已知的致癌基因分类。 突变型T-ag
多肽将在结构上和生物化学上表征,
包括与膜蛋白形成复合物,
与突变体的转化有关。 ⑶贩运SV 40 T-
将研究Ag对细胞表面的影响。 缺失突变体将揭示
T-ag中短疏水序列对转运的可能影响
和膜的相互作用。 可能与细胞热量有关-
将阐述pmT-ag转运中休克蛋白p73(结合T-ag)。
O-糖基化在运输或膜结合中的作用
将予以考虑。 (4)参与muoti的细胞和分子事件
将定义SV 40转基因小鼠肝脏中的阶段致癌作用。
我们发现,携带由α-1-
抗胰蛋白酶启动子促进肝肿瘤的发生。 新的转基因小鼠携带
将制备p53或突变体T-ag基因。 各种转基因株系
将进行杂交并确定子代动物的病理学。 的
病毒(pmT-ag)和细胞(癌基因)事件的表达将被
与肿瘤进展的不同阶段相关。 增生性
将培养肝细胞以确定体外生长特性,
对应于体内的癌前病变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JANET S BUTEL其他文献
JANET S BUTEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JANET S BUTEL', 18)}}的其他基金
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 19.4万 - 项目类别:
Research Grant
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 19.4万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 19.4万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 19.4万 - 项目类别:
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 19.4万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 19.4万 - 项目类别:
Studentship Programs
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 19.4万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
9922602 - 财政年份:2020
- 资助金额:
$ 19.4万 - 项目类别: